Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nizar Y Saad

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
RNA (New York, N.Y.)|August 16, 2015
A glyS T-box riboswitch with species-specific structural features responding to both proteinogenic and nonproteinogenic tRNAGly isoacceptorsMaria Apostolidi, Nizar Y Saad, Denis Drainas, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2013
Two-codon T-box riboswitch binding two tRNAsNizar Y Saad, Vassiliki Stamatopoulou, Mélanie Brayé, et al.
The Journal of Biological Chemistry|April 17, 2012
Riboswitch (T-box)-mediated control of tRNA-dependent amidation in Clostridium acetobutylicum rationalizes gene and pathway redundancy for asparagine and asparaginyl-trnaasn synthesisNizar Y Saad, Bettina Schiel, Mélanie Brayé, et al.
FEBS Letters|June 6, 2022
The DUX4 protein is a co-repressor of the progesterone and glucocorticoid nuclear receptorsJulieta Quintero, Nizar Y Saad, Sabrina M Pagnoni, et al.
Medrxiv : the Preprint Server for Health Sciences|December 9, 2024
Identification of disease-specific extracellular vesicle-associated plasma protein biomarkers for Duchenne Muscular Dystrophy and Facioscapulohumeral Muscular DystrophyMustafa Bilal Bayazit, Don Henderson, Kim Truc Nguyen, et al.
Nature Communications|December 9, 2021
Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophyNizar Y Saad, Mustafa Al-Kharsan, Sara E Garwick-Coppens, et al.
Molecular Therapy. Methods & Clinical Development|February 2, 2018
Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHDLindsay M Wallace, Nizar Y Saad, Nettie K Pyne, et al.
Annals of Clinical and Translational Neurology|May 21, 2026
Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHDMustafa Bilal Bayazit, Chiranth K Nagaraj, Jackson S Newell, et al.
Annals of Neurology|May 15, 2023
Post-Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell ModelsRenatta N Knox, Jocelyn O Eidahl, Lindsay M Wallace, et al.
Molecular Therapy. Nucleic Acids|April 8, 2026
Safety, efficacy, and distal nerve Schwann cell biodistribution in mice and NHPs to support translation of AAV9 RNAi therapy for CMT1AMarina Stavrou, Lindsay M Wallace, Merlin P Thangaraj, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
RNA (New York, N.Y.)|August 16, 2015
A glyS T-box riboswitch with species-specific structural features responding to both proteinogenic and nonproteinogenic tRNAGly isoacceptorsMaria Apostolidi, Nizar Y Saad, Denis Drainas, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2013
Two-codon T-box riboswitch binding two tRNAsNizar Y Saad, Vassiliki Stamatopoulou, Mélanie Brayé, et al.
The Journal of Biological Chemistry|April 17, 2012
Riboswitch (T-box)-mediated control of tRNA-dependent amidation in Clostridium acetobutylicum rationalizes gene and pathway redundancy for asparagine and asparaginyl-trnaasn synthesisNizar Y Saad, Bettina Schiel, Mélanie Brayé, et al.
FEBS Letters|June 6, 2022
The DUX4 protein is a co-repressor of the progesterone and glucocorticoid nuclear receptorsJulieta Quintero, Nizar Y Saad, Sabrina M Pagnoni, et al.
Medrxiv : the Preprint Server for Health Sciences|December 9, 2024
Identification of disease-specific extracellular vesicle-associated plasma protein biomarkers for Duchenne Muscular Dystrophy and Facioscapulohumeral Muscular DystrophyMustafa Bilal Bayazit, Don Henderson, Kim Truc Nguyen, et al.
Nature Communications|December 9, 2021
Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophyNizar Y Saad, Mustafa Al-Kharsan, Sara E Garwick-Coppens, et al.
Molecular Therapy. Methods & Clinical Development|February 2, 2018
Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHDLindsay M Wallace, Nizar Y Saad, Nettie K Pyne, et al.
Annals of Clinical and Translational Neurology|May 21, 2026
Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHDMustafa Bilal Bayazit, Chiranth K Nagaraj, Jackson S Newell, et al.
Annals of Neurology|May 15, 2023
Post-Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell ModelsRenatta N Knox, Jocelyn O Eidahl, Lindsay M Wallace, et al.
Molecular Therapy. Nucleic Acids|April 8, 2026
Safety, efficacy, and distal nerve Schwann cell biodistribution in mice and NHPs to support translation of AAV9 RNAi therapy for CMT1AMarina Stavrou, Lindsay M Wallace, Merlin P Thangaraj, et al.
Pageof 2